New drug cocktail aims to cure EBV-Linked throat cancer
NCT ID NCT06592599
First seen Feb 11, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tests whether adding a new drug combination (gemcitabine, docetaxel, and toripalimab) before standard radiation can safely and effectively cure a specific type of throat cancer (nasopharyngeal carcinoma) linked to the Epstein-Barr virus. About 24 adults with advanced but non-spread cancer will receive three cycles of the drug combo, followed by radiation. The goal is to see if this approach can eliminate the cancer and allow patients to stop all treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.